Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

NEW YORK, April 28, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the final dataset from the Phase 3 short-term clinical trial of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.  The Zerenex data was presented earlier today at the National Kidney Foundation Spring Clinical Meetings being held in Las Vegas, Nevada, in an oral presentation by David S. Goldfarb, M.D., Clinical Chief of Nephrology, NYU Langone Medical Center, Professor of Medicine & Physiology, NYU School of Medicine.  On November 30, 2010, the Company issued a press release announcing positive top-line results from this Phase 3 short-term study.

Phase 3 short-term study designThis Phase 3 study was a multicenter, randomized, open-label trial with a two-week washout period, following which patients were randomized 1:1:1 to receive a fixed dose of Zerenex of either 1 gram, 6 grams or 8 grams per day for a treatment period of 28 days. Zerenex was administered using a 1 gram oral caplet formulation, hence, the fixed-dose arms of 1 gram, 6 grams and 8 grams per day represent 1, 6 and 8 pills per day, respectively.

One hundred fifty-one dialysis patients were enrolled into the study. The Intent-to-Treat (ITT) group included 146 patients, representing all patients who took at least one dose of Zerenex and provided a Baseline (at the end of washout) and at least one post-Baseline efficacy assessment. Efficacy assessments were taken weekly starting at Baseline and subsequently at days 7, 14, 21 and 28.

EFFICACY DATA ANALYSESThe primary endpoint of the study was to determine whether there was a dose response in the change in serum phosphorus from Baseline to Day 28 in the ITT group, using a regression analysis to evaluate this objective.

The study met the primary endp
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... City, Ca. (PRWEB) August 28, 2014 ... E3 rating for an alcohol-based hand sanitizer, asks food ... harvest by comparing the hand sanitizer they’re currently using ... Spray . Hand hygiene is critical to fighting cross-contamination ... environment. Best Sanitizers believes there are key criteria ...
(Date:8/28/2014)... Grove, PA (PRWEB) August 28, 2014 ... and create a culture that will allow individuals to ... are becoming increasingly important for employers looking to compete ... science industries are embracing this trend, as the sector ... fabric of a company, which will have real results ...
(Date:8/28/2014)... by a Florida State University research team has led ... temperature, emit white light, and convert photon energy directly ... a butterfly. , Biwu Ma, associate professor in the ... College of Engineering, created the molecule in a lab ... that his creation has many other unique capabilities. , ...
(Date:8/28/2014)... August 28, 2014 Supplementing their ... a promotion for Eppendorf Safe Lock Centrifuge ... purchase the highest quality tubes at an affordable ... for customers doing chemical, medical, pharmaceutical, and life ... are not regularly able to afford Eppendorf products. ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Inc. (OTC Bulletin Board: GNLK, www.genelinkbio.com ) today ... private label distribution partnership serving the healthcare and wellness ... gives GeneLink reach into new areas of the rapidly ... available to us.  The HelixLife team is very experienced ...
... From the U.S. Food and Drug Administration Duchenne... -- AMSTERDAM, September 24, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... GeneLink, Inc. (OTC Bulletin Board: ... pleased to report that the Superior Court of Pennsylvania ... the Company,s former CEO and President, John DePhillipo, and ... subsidiary GeneWize Life Sciences, Inc., and several of the ...
Cached Biology Technology:GeneLink Announces HelixLife Private Label Distribution Agreement 2AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy 2AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy 3AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy 4AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy 5AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy 6AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy 7AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy 8
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) ... the American College of Sports Medicine,s Conference on ... in Miami, Florida. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the American ...
(Date:8/28/2014)... . Cars, planes ... of sophisticated assembly lines. Mobile assembly carriers, on to which ... assembly lines. In the case of a car body, the ... a precise spatial and chronological sequence, resulting in a complete ... of such an assembly line at molecular level has been ...
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3Paleontology: Oldest representative of a weird arthropod group 2
... at levels consumed by breast cancer patients and survivors in ... rats, new research found., The role of folate, a ... development and progression of breast cancer is highly controversial. ... breast cancer, recent studies have suggested that taking high amounts ...
... When the temperature rises on Baffin Island, in the ... ice for thousands of years, are exposed. Using radiocarbon ... has calculated the age of relic moss samples that ... moss samples would have been destroyed by erosion had ...
... the Montreal Neurological Institute and Hospital in Canada ... Parkinson,s disease are involved in the early-stage quality ... reported in T he EMBO Journal , removes ... mitochondria., "PINK1 and parkin, are implicated in selectively ...
Cached Biology News:Large amounts of folic acid shown to promote growth of breast cancer in rats 2Quality control of mitochondria as a defense against disease 2
... Model 1575 immunowash microplate washer 100-240 V, ... have flat-, U-, or V-bottom wells. The ... and vertical needle positions to an accuracy ... aspiration, and overflow washing. It can store ...
... MULTI-FUN Incubator is a compact benchtop ... a microprocessor controller with a large ... and agitation speed. Air circulation inside ... incubator. Temperature can be easily calibrated ...
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
Biology Products: